FR3116439B1 - Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects - Google Patents

Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects Download PDF

Info

Publication number
FR3116439B1
FR3116439B1 FR2012208A FR2012208A FR3116439B1 FR 3116439 B1 FR3116439 B1 FR 3116439B1 FR 2012208 A FR2012208 A FR 2012208A FR 2012208 A FR2012208 A FR 2012208A FR 3116439 B1 FR3116439 B1 FR 3116439B1
Authority
FR
France
Prior art keywords
active ingredient
film
active principle
coated tablet
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2012208A
Other languages
French (fr)
Other versions
FR3116439A1 (en
Inventor
Antoine Noel
Paul Violette
Sarah Oddoux
Magali Hamelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Dielen
Original Assignee
Laboratoire Dielen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoire Dielen filed Critical Laboratoire Dielen
Priority to FR2012208A priority Critical patent/FR3116439B1/en
Publication of FR3116439A1 publication Critical patent/FR3116439A1/en
Application granted granted Critical
Publication of FR3116439B1 publication Critical patent/FR3116439B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

La présente invention concerne un comprimé pelliculé contenant au moins un principe actif (P2, P3) et une combinaison d’excipients (E2, E3), adapté à l’administration par voie orale dudit au moins un principe actif (P2, P3) chez des sujets humains. Le comprimé pelliculé (1) comprend : - un pelliculage (2) comprenant au moins un principe actif (P2) qui est dispersé dans au moins un premier excipient (E2), lequel pelliculage (2) est conçu pour une libération sublinguale immédiate dudit au moins un principe actif (P2) en vue d’une absorption par voie sublinguale, - un noyau (3) comprenant au moins un principe actif (P3) qui est dispersé dans au moins un second excipient (E3), lequel noyau (3) est conçu pour une libération intestinale différée d’au moins une partie dudit au moins un principe actif (P3) en vue d’une absorption par voie intestinale. Figure pour l’abrégé : 1The present invention relates to a film-coated tablet containing at least one active principle (P2, P3) and a combination of excipients (E2, E3), suitable for the oral administration of said at least one active principle (P2, P3) in human subjects. The film-coated tablet (1) comprises: - a film-coating (2) comprising at least one active principle (P2) which is dispersed in at least one first excipient (E2), which film-coating (2) is designed for immediate sublingual release of said at least at least one active principle (P2) with a view to absorption by the sublingual route, - a core (3) comprising at least one active principle (P3) which is dispersed in at least one second excipient (E3), which core (3) is designed for delayed intestinal release of at least a portion of said at least one active principle (P3) with a view to absorption via the intestinal route. Figure for abstract: 1

FR2012208A 2020-11-26 2020-11-26 Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects Active FR3116439B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR2012208A FR3116439B1 (en) 2020-11-26 2020-11-26 Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2012208A FR3116439B1 (en) 2020-11-26 2020-11-26 Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects
FR2012208 2020-11-26

Publications (2)

Publication Number Publication Date
FR3116439A1 FR3116439A1 (en) 2022-05-27
FR3116439B1 true FR3116439B1 (en) 2023-08-04

Family

ID=74125531

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2012208A Active FR3116439B1 (en) 2020-11-26 2020-11-26 Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects

Country Status (1)

Country Link
FR (1) FR3116439B1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
FR2889811B1 (en) * 2005-08-19 2009-10-09 Sanofi Aventis Sa ASSOCIATION OF A HYPNOTIC AGENT HAS LONG LASTING ACTION AND A SHORT-ACTING HYPNOTIC AGENT, A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND ITS THERAPEUTIC USE.
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Also Published As

Publication number Publication date
FR3116439A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
ES2577930T3 (en) Triazine derivatives to delay the onset of type 1 diabetes
Vogel et al. Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor lopinavir/ritonavir in liver‐transplanted HIV‐infected patients
BR9909672A (en) use of an active medicinal compound in the preparation of a medicament for the treatment of hypertension
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
MA29744B1 (en) SOLID DOSAGE FORMULATIONS OF MEDICAMENTS HAVING IMPROVED ORAL ADSORPTION
US20080145458A1 (en) Formulations useful in the treatment of male and female impotence
MA33491B1 (en) Pharmaceutical formulations of hepatitis c virus enzyme inhibitor
HUP9900457A2 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
MA27710A1 (en) PALONOSETRONE LIQUID PHARMACEUTICAL FORMULATIONS
HUP0204109A2 (en) Oral preparations for diabetes
PT1658854E (en) Formulations useful in the treatment of male and female impotence
DE60129330T2 (en) USE OF COX-2 INHIBITORS AS IMMUNOSTIMULANTS FOR THE TREATMENT OF HIV OR AIDS
US20160184332A1 (en) Medicament comprising a pharmaceutical combination of drugs
HUP0401429A2 (en) Pharmaceutical composition comprising lumiracoxib
FR3116439B1 (en) Film-coated tablet containing at least one active ingredient, suitable for oral administration of said at least one active ingredient in human subjects
RU2003109606A (en) PHARMACEUTICAL COMPOSITIONS
Fang et al. Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects
Cheung et al. Never too old for statin treatment?
JP7219898B2 (en) Blood purification with alkaline agents
EP2314312A3 (en) Peptides and therapeutic application therefof
HUP0203148A2 (en) Orally distintegrating composition comprising mirtazapine
US4880742A (en) Prostaglandin biosynthesis inhibitors
NO20054320L (en) Therapeutic agent for hemorrhoids disease
BRPI0415322A (en) antiretroviral pharmaceutical composition, process for the preparation of an antiretroviral pharmaceutical composition, method for reducing the burden of pill consumption for a patient, method for increasing lamivudine and zidovudine half-life while not affecting nevirapine half-life
AR083393A1 (en) PHARMACEUTICAL COMPOSITION LIQUID FOR THE TREATMENT AND PREVENTION OF PAIN

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220527

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4